Articles by Adeline Siew, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Adeline Siew, PhD

Seattle Genetics Forms ADC Pact with Bayer

Seattle Genetics could potentially receive approximately $500 million in fees, milestones and royalties.
Jul 3, 2013

Seattle Genetics could potentially receive approximately $500 million in fees, milestones and royalties.

Controlling Drug Release Through Osmotic Systems

Osmotic systems offer versatility for delivering drugs with varied properties and dosage requirements.
Jul 2, 2013

Osmotic systems offer versatility for delivering drugs with varied properties and dosage requirements.

2013 CPhI Pharma Awards Now Open

Entries open to any company across three categories - formulation, process development and best packaging.
Jun 24, 2013

Entries open to any company across three categories - formulation, process development and best packaging.

EC Fines Lundbeck Over 'Pay-for-Delay' Deals in Europe

Lundbeck and eight other pharmaceutical companies have been fined for delaying generic entry of the blockbuster antidepressant, Celexa (citalopram), into the market.
Jun 21, 2013

Lundbeck and eight other pharmaceutical companies have been fined for delaying generic entry of the blockbuster antidepressant, Celexa (citalopram), into the market.

Industry Perspectives: Achieving Solutions for the Challenge of Poorly Water-Soluble Drugs

A multifaceted approach is needed to resolve the myriad of challenges in developing oral formulations of poorly soluble drugs.
Jun 2, 2013

A multifaceted approach is needed to resolve the myriad of challenges in developing oral formulations of poorly soluble drugs.

Amgen and Astellas Form Joint Venture to Address Unmet Medical Needs in Japan

May 29, 2013

Amgen and Astellas have entered into a strategic alliance to provide new medicines for serious unmet medical needs of Japanese patients. The alliance leverages the complementary capabilities of both companies through an innovative business model that combines Amgen's pipeline candidates with Astellas' deep knowledge of Japanese patient and physician needs, long-term commercial and regulatory experience, and strong presence as a leading company in Japan.

Novo Acquires Xellia for US$ 700 Million

May 22, 2013

Novo A/S, the holding company of Denmark's Novo Nordisk, has acquired Xellia Pharmaceuticals and purchased all shares of the group for approximately US$ 700 million.

Pfizer Halts Phase III Trial of Cancer Drug in NHL Due to Futility

May 22, 2013

Pfizer has discontinued a Phase III study of its investigational cancer drug, inotuzumab ozogamicin, in relapsed or refractory aggressive non-Hodgkin lymphoma (NHL) after it failed to show benefit in overall survival.

AbbVie and Galapagos Extend GLPG0634 Collaboration

May 21, 2013

AbbVie and Galapagos have extended their collaboration on the clinical development of GLPG0634 to include Crohn's disease.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here